Boston Scientific's REBEL coronary stent system receives CE mark
13 March 2014
Boston Scientific Corporation has received EU approval for its
REBEL Platinum Chromium Coronary Stent System, the company's latest
generation bare metal stent for the treatment of coronary artery
The REBEL Stent System offers the same stent platform as the
Promus PREMIER drug eluting stent (DES) but without the Everolimus
drug. Bare metal stents continue to play an important role in
the treatment of coronary artery disease and represent a significant
portion of the global stent market.
"I am glad to have a bare metal stent that performs like the
PREMIER DES but allows me to treat patients who are not candidates
for DES therapy," said Prof. Didier Carrie, M.D., Ph.D., an
investigator for the OMEGA clinical trial at Centre Hopital
Universitaire, Rangueil, France. "In addition to its great
visibility and deliverability, the platinum chromium stent
architecture features low recoil that is particularly important for
patients treated with bare metal stents."
The REBEL Stent System features unparalleled visibility, low
recoil, exceptional radial strength and fracture resistance, while
improving axial strength and deliverability. Its enhanced
low-profile delivery system also features a shorter, more visible
tip, a dual-layer balloon and a Bi-Segment™ inner lumen catheter
designed to facilitate precise stent delivery across challenging
CAD is a narrowing of blood vessels that supply blood and oxygen
to the heart. Patients with CAD may experience pain, shortness of
breath and fatigue. They may also be at risk for a heart attack.
A primary treatment for CAD is the placement of a stent in the
artery to help keep it open and allow the blood to flow more freely.